Close Menu

NEW YORK – Sequencing instrument and services firm SeqLL last week halted plans for an $8 million initial public offering.

In an April 24 filing with the US Securities and Exchange Commission, CFO John Kennedy requested withdrawal of SeqLL's Form S-1 registration statement, initially filed April 2019. The firm had planned to offer approximately 1.4 million shares of common stock at an IPO price between $5.40 and $6.40 per share. It would have traded on the Nasdaq under ticker symbol "SQL." WallachBeth Capital was the sole bookrunning manager for the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.